UNSPSC 51294523: Paroxetine mesilate or mesylate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C19H20FNO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M711N184JE, chemically known as piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s,4r)-, methanesulfonate (1:1), but more generally known as paroxetine mesylate, which bears US NIH Compound Identifier 206527.

UNSPSC 51294523 Paroxetine mesilate or mesylate is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities posted under this code — Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's request for information on direct-to-manufacturer prescription programs, and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products — involve pharmaceutical procurement and distribution but target different product families and do not center on paroxetine or antidepressant medications specifically. The code shows little relevant recent activity for the narrow pharmaceutical product it nominally covers; the tagging mismatch suggests that state and local issuing bodies are using this code as a catch-all for broader pharmaceutical commodity procurement rather than for the specific active pharmaceutical ingredient the code name identifies.

The issuing bodies include state health agencies (Texas Health and Human Services Commission), county health departments (Seminole County, Florida), and multistate cooperative purchasing alliances (Minnesota MMCAP serving Minnesota and Oregon members). Geographic activity appears in Florida, Texas, Minnesota, and Oregon, though the cooperative purchasing vehicle extends reach across multiple participating jurisdictions. The Seminole County IFB, posted June 30, 2026 with response due July 26, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries. The Texas HHS RFI, posted April 3, 2026, gathered vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with contract term starting July 1, 2026 and performance weighted 75 percent on price competitiveness.